Genitourinary Cancers | Specialty

Pembrolizumab/Axitinib Combo Approved in Europe for Frontline RCC

September 4th 2019

The European Commission has approved the combination of pembrolizumab (Keytruda) and axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma.

Dr. Joseph on Molecular Signatures in mRCC

September 4th 2019

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses molecular signatures in metastatic renal cell carcinoma (mRCC).

Dr. Hurwitz on Patient Cohorts in the PIVOT-02 Trial

August 30th 2019

Michael E. Hurwitz, MD, PhD, assistant professor of medicine, Yale Cancer, Center, discusses the various patient cohorts in the ongoing phase I/II PIVOT-02 trial.

Ilixadencel Plus Sunitinib Induces Complete Responses in Metastatic RCC

August 29th 2019

The combination of the off-the-shelf cancer immune primer ilixadencel and sunitinib elicited a 11% complete response rate in patients with metastatic renal cell carcinoma, according to topline findings from the phase II MERECA trial (NCT02432846).

Precision Medicine to Take Hold in Advanced Bladder Cancer

August 26th 2019

Parminder Singh, MD, discusses ongoing research in advanced urothelial cancer and the focus on incorporating precision medicine in the field.

Clearing Up Confusion on Cytoreductive Nephrectomy in mRCC

August 20th 2019

David D. Thiel, MD, provides perspective on the CARMENA findings in metastatic renal cell carcinoma.

New and Emerging Immunotherapy Combos for Advanced RCC: Finding the Right Treatments

August 16th 2019

Emerging immunotherapy combinations have offered a strong challenge to sunitinib (Sutent) in the setting of frontline advanced clear cell renal cell carcinoma.

Dr. Thiel on Surgical Advances for RCC

August 15th 2019

David D. Thiel, MD, chair, Department of Urology, Mayo Clinic, discusses the advancements in surgical techniques for renal cell carcinoma.

Vicinium Elicits Promising Responses in BCG-Unresponsive Bladder Cancer

August 13th 2019

Vicinium led to 6- and 12-month complete response rates in patients with high-risk non-muscle invasive bladder cancer who did not respond to Bacillus Calmette-Guérin therapy, according to updated results of the phase III VISTA trial.

Distinguishing Between Frontline Monotherapies and Combos in mRCC

August 12th 2019

Richard W. Joseph, MD, discusses the factors that must be considered when selecting the appropriate frontline treatment for patients with metastatic renal cell carcinoma, the need for clarity regarding the role of cytoreductive nephrectomy, as well as the research that is being done in those with rarer subtypes of kidney cancer.

Dr. Thiel on Resectability in mRCC

August 10th 2019

David D. Thiel, MD, chair, Department of Urology, Mayo Clinic, discusses resectability in metastatic renal cell carcinoma (mRCC).

Dr. Joseph on Factors Influencing Frontline Therapy Selection in mRCC

August 5th 2019

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses considerations for frontline therapy selection in metastatic renal cell carcinoma (mRCC).

Dr. Thiel on Overall Survival Data From the CARMENA Trial in mRCC

August 2nd 2019

David D. Thiel, MD, chair, Department of Urology, Mayo Clinic, discusses the phase III randomized CARMENA trial, which examined cytoreductive nephrectomy plus sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma.

Dr. Singh on the Prevalence of Genomic Testing in Urothelial Cancer

August 1st 2019

Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses the prevalence of genomic testing in urothelial cancer.

Advances and Challenges Faced in the Treatment of mRCC

July 29th 2019

Biomarkers: Guide to Clinical Decision Making to Treat mRCC

July 29th 2019

NKTR-214 and COSMIC-313 for Previously Untreated RCC

July 29th 2019

Ongoing Clinical Trials for Metastatic RCC

July 29th 2019

Third-Line Therapy and Beyond in Treating Metastatic RCC

July 29th 2019

Safety and Tolerability Influence the Use of TKIs in RCC

July 29th 2019